Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
The most recent EPS for Standard BioTools Inc is $0.33, beating expectations of $-0.04.
How did Standard BioTools Inc LAB's revenue perform in the last quarter?
Standard BioTools Inc revenue for the last quarter is $0.33
What is the revenue estimate for Standard BioTools Inc?
According to 3 of Wall street analyst, the revenue estimate of Standard BioTools Inc range from $19.73M to $17.67M
What's the earning quality score for Standard BioTools Inc?
Standard BioTools Inc has a earning quality score of B+/48.26496. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Standard BioTools Inc report earnings?
Standard BioTools Inc next earnings report is expected in 2026-08-03
What are Standard BioTools Inc's expected earnings?
Standard BioTools Inc expected earnings is $17.99M, according to wall-street analysts.
Did Standard BioTools Inc beat earnings expectations?
Standard BioTools Inc recent earnings of $21.14M beat expectations.